China reported another gene editing death tied to a young patient receiving HG-302 for Duchenne muscular dystrophy, according to disclosures by Huidagene Therapeutics. The report follows earlier coverage of a gene editing death in China two weeks prior involving Snijders Blok-Campeau syndrome. The event raises immediate concerns about oversight, patient selection, and risk mitigation as gene-editing programs expand beyond early-phase proof-of-concept into broader clinical activity. The company’s update adds to regulatory and ethics pressure around first-in-human and subsequent gene editing administration. For biotech and clinicians, the development underscores how safety scrutiny can abruptly change the execution path for platform operators in rapidly scaling jurisdictions.